Difficulty: Medium
Average Score: 71%
Practice
A 72-year-old woman with Parkinson's disease is taking a medication that increases release of dopamine, blockade of cholinergic receptors, and inhibiting the N-methyl-D-aspartate receptor. This describes which of the following agents?
Correct answer
A
Rationale
The correct answer is A) Amantadine.
Amantadine is an antiviral medication that also exhibits properties beneficial for Parkinson's disease. It increases the release of dopamine, blocks cholinergic receptors, and inhibits the N-methyl-D-aspartate receptor, which collectively help alleviate symptoms of Parkinson's disease.
Now let's discuss why the other options are incorrect:
B) Bromocriptine is a dopamine agonist that acts directly on dopamine receptors, but it does not have the same mechanism of action as described in the question.
C) Pramipexole is another dopamine agonist used in Parkinson's disease, but it does not exhibit the specific combination of actions mentioned in the question.
D) Rotigotine is a dopamine agonist delivered through a transdermal patch and does not match the described mechanism of action.
Educational context:
Understanding the mechanisms of action of CNS drugs is crucial for healthcare professionals managing patients with neurological disorders. By knowing how each drug works, healthcare providers can make informed decisions about treatment options based on the unique needs of each patient. In the case of Parkinson's disease, selecting the most appropriate medication with the right mechanism of action can significantly impact patient outcomes and quality of life.
Amantadine is an antiviral medication that also exhibits properties beneficial for Parkinson's disease. It increases the release of dopamine, blocks cholinergic receptors, and inhibits the N-methyl-D-aspartate receptor, which collectively help alleviate symptoms of Parkinson's disease.
Now let's discuss why the other options are incorrect:
B) Bromocriptine is a dopamine agonist that acts directly on dopamine receptors, but it does not have the same mechanism of action as described in the question.
C) Pramipexole is another dopamine agonist used in Parkinson's disease, but it does not exhibit the specific combination of actions mentioned in the question.
D) Rotigotine is a dopamine agonist delivered through a transdermal patch and does not match the described mechanism of action.
Educational context:
Understanding the mechanisms of action of CNS drugs is crucial for healthcare professionals managing patients with neurological disorders. By knowing how each drug works, healthcare providers can make informed decisions about treatment options based on the unique needs of each patient. In the case of Parkinson's disease, selecting the most appropriate medication with the right mechanism of action can significantly impact patient outcomes and quality of life.